Moleculin Biotech Files 8-K

Ticker: MBRX · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1659617

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Moleculin Biotech filed an 8-K on Dec 17, 2025. Check for updates.

AI Summary

Moleculin Biotech, Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.

Why It Matters

This filing indicates Moleculin Biotech, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a high-risk event.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The 8-K filing is for Moleculin Biotech, Inc. and serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K report filed and what is the earliest event date reported?

The report was filed as of December 17, 2025, and the earliest event reported is also December 17, 2025.

What is Moleculin Biotech, Inc.'s state of incorporation and IRS Employer Identification No.?

Moleculin Biotech, Inc. is incorporated in Delaware and its IRS Employer Identification No. is 47-4671997.

What is the principal executive office address for Moleculin Biotech, Inc.?

The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

What is Moleculin Biotech, Inc.'s SIC code?

Moleculin Biotech, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-17 08:30:12

Filing Documents

01

Item 7.01 Regulation FD Disclosure On December 17, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release announcing announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta led by pediatric oncologist, Tobey MacDonald, MD, who discovered STAT3 is critical to certain childhood brain tumors and currently serves as Professor of Pediatrics and Director of the Pediatric Neuro-Oncology Program. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 17, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: December 17, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing